183 related articles for article (PubMed ID: 25715498)
1. [Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C].
Burnevich EZ
Ter Arkh; 2014; 86(11):105-14. PubMed ID: 25715498
[TBL] [Abstract][Full Text] [Related]
2. Simeprevir for the treatment of chronic hepatitis C.
You DM; Pockros PJ
Expert Opin Pharmacother; 2013 Dec; 14(18):2581-9. PubMed ID: 24138198
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
4. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
Hayashi N; Seto C; Kato M; Komada Y; Goto S
J Gastroenterol; 2014 Jan; 49(1):138-47. PubMed ID: 24005956
[TBL] [Abstract][Full Text] [Related]
5. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
[TBL] [Abstract][Full Text] [Related]
7. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
Takehara T
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):909-17. PubMed ID: 24882512
[TBL] [Abstract][Full Text] [Related]
8. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
9. [A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
Suzuki S; Izumi N
Nihon Rinsho; 2015 Feb; 73(2):266-72. PubMed ID: 25764681
[TBL] [Abstract][Full Text] [Related]
10. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R
Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518
[TBL] [Abstract][Full Text] [Related]
11. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
Izumi N; Hayashi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
J Gastroenterol; 2014 May; 49(5):941-53. PubMed ID: 24626851
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
[TBL] [Abstract][Full Text] [Related]
13. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
14. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
15. Emerging treatments for hepatitis C.
Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
[TBL] [Abstract][Full Text] [Related]
16. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
[TBL] [Abstract][Full Text] [Related]
18. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
Fried MW; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson I; Marcellin P; Manns M; Nikitin I; Poordad F; Sherman M; Zeuzem S; Scott J; Gilles L; Lenz O; Peeters M; Sekar V; De Smedt G; Beumont-Mauviel M
Hepatology; 2013 Dec; 58(6):1918-29. PubMed ID: 23907700
[TBL] [Abstract][Full Text] [Related]
19. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.
Maekawa S; Enomoto N
J Gastroenterol; 2014 Jan; 49(1):163-4. PubMed ID: 24356811
[No Abstract] [Full Text] [Related]
20. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
